ISCT Asia Regional Meeting Singapore

Date : 2026-04-30

Publisher : Cytoniche | Marketing

September 2-5, 2026 | Suntec Convention Centre, Singapore

Exhibit Hall | Booth #14

The ISCT Asia Regional Meeting 2026 concluded in Singapore, bringing together leading voices from the cell and gene therapy community to discuss the technologies and strategies shaping the next stage of advanced therapy development.

During the meeting, CytoNiche showcased its 3D FloTrix™ Intelligent Cell Manufacturing Platform at Booth #19, presenting an integrated approach to addressing key challenges in cell manufacturing, including scalability, process consistency, automation, and cost efficiency.

The 3D FloTrix™ platform integrates automated bioreactor systems, advanced 3D microcarrier technologies, and optimised downstream processing solutions to support controlled and scalable cell production. The platform is designed to facilitate the development of robust manufacturing processes and enable a more seamless transition from laboratory-scale research to clinical and commercial manufacturing.

Throughout the event, the CytoNiche team engaged with professionals across the cell and gene therapy ecosystem, with discussions centred on process development, manufacturing scale-up, automation, process standardisation, and the implementation of scalable production strategies. These exchanges provided valuable opportunities to understand the evolving requirements of the industry and to explore potential applications of integrated manufacturing technologies across different cell therapy workflows.

As the cell and gene therapy industry continues to progress towards clinical translation and commercialisation, scalable and reproducible manufacturing remains a critical consideration. The growing adoption of automation and integrated processing technologies is expected to play an increasingly important role in improving manufacturing efficiency while maintaining process control and product consistency.

CytoNiche remains committed to advancing innovative manufacturing technologies that support the industrialisation of cell therapies. Through the continued development of the 3D FloTrix™ platform and its associated technologies, CytoNiche aims to provide integrated solutions that address manufacturing requirements across the development lifecycle, from process development and scale-up to clinical and commercial production.

CytoNiche would like to thank all visitors, partners, and industry professionals who engaged with the team during the ISCT Asia Regional Meeting 2026. The company looks forward to building on these discussions and continuing to contribute to the advancement of scalable cell manufacturing in Asia and globally.

ACTO – Asian Cellular Therapy Organization

29th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)